GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-01-19
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT00101946
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-11-24
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00097409
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 261
- Registration Number
- NCT00097331
- Locations
- 🇪🇸
GSK Investigational Site, Malaga, Spain
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00097370
- Locations
- 🇮🇹
GSK Investigational Site, Bologna, Emilia-Romagna, Italy
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
- Conditions
- HIV Infection
- First Posted Date
- 2004-10-18
- Last Posted Date
- 2010-09-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 900
- Registration Number
- NCT00094367
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
HuMax-CD20 in Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00093314
- Locations
- 🇺🇸
University of Iowa, Hospitals and Clinics, Iowa City, Iowa, United States
Major Depressive Disorder In The Elderly
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2004-10-07
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 364
- Registration Number
- NCT00093288
- Locations
- 🇷🇺
GSK Investigational Site, Moscow, Russian Federation
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
- Conditions
- Lymphoma, Follicular
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00092274
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00002767
- Locations
- 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸Creighton University Cancer Center, Omaha, Nebraska, United States
Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2004-08-26
- Last Posted Date
- 2006-02-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00090077
- Locations
- 🇺🇸
GSK Clinical Trials Call Center, Seattle, Washington, United States